Search
Rigel Pharmaceuticals Inc
RIGLAdd to Watchlist
44.460USD
-1.230-2.69%
Close 11-13 16:00（ET）
830.51MMarket Cap
2.20P/E TTM
Rigel Pharmaceuticals Inc (RIGL) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Rigel Pharmaceuticals Inc in the past month.
Buy
2 Strong Buy
1 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
63.000USD+22.78%
RIGL Analyst Recommendation Trends
In the current month, RIGL has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RIGL average Analyst price target in the last month is 63.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
2
2
2
2
2
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
6
6
6
RIGL Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Apple Inc
AAPL
9
16
14
3
1
43
Ge Vernova Inc
GEV
10
21
6
1
0
38
Tapestry Inc
TPR
5
12
4
1
0
22
Verisk Analytics Inc
VRSK
5
6
9
0
0
20
FMC Corp
FMC
1
4
12
2
0
19
Avantor Inc
AVTR
1
1
15
1
0
18
Elanco Animal Health Inc
ELAN
5
9
2
0
0
16
Genuine Parts Co
GPC
2
3
8
0
0
13
Canadian Solar Inc
CSIQ
1
3
6
3
0
13
Fate Therapeutics Inc
FATE
3
3
6
0
0
12
Financial Forecasting
Based on analysts' estimates, RIGL EPS is projected to reach 0.875 in FY2026Q4, following reported EPS of 0.705 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
0.76
0.62
0.84
0.88
0.52
Actual
0.47
0.93
0.70
--
--
Surprise
-38.16%
+50.41%
-15.77%
--
--
FAQs
What is Rigel Pharmaceuticals Inc's expected revenue for the next quarter?
Rigel Pharmaceuticals Inc's expected revenue is 91.00M.
What is Rigel Pharmaceuticals Inc's price target?
Analysts forecast that Rigel Pharmaceuticals Inc's price target is USD 63.00, with the highest forecast at USD 85.00 and the lowest forecast at USD 43.00.
How have Rigel Pharmaceuticals IncRIGL's recent earnings per share performed?
The market expectation was USD 0.70, while Rigel Pharmaceuticals IncRIGL's earnings per share (EPS) for the previous quarter was USD 0.93. EPS for the next quarter is expected at USD 0.88.
What is the analyst rating for Rigel Pharmaceuticals Inc?
Based on the ratings of Rigel Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.